Medtronic 2013 Annual Report Download - page 22

Download and view the complete annual report

Please find page 22 of the 2013 Medtronic annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 145

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145

75732me_10K.indd 7 6/25/13 6:39 PM
Table of Contents
Customers and Competitors
The primary medical specialists who use our Coronary products are interventional cardiologists. Our primary competitors in the
Coronary business are Abbott Laboratories (Abbott) and Boston Scientific.
Structural Heart
The Structural Heart business offers a comprehensive line of products and therapies to treat a variety of heart valve disorders. Our
products include products for the repair and replacement of heart valves, perfusion systems, positioning and stabilization systems
for beating heart revascularization surgery, and surgical ablation products.
The following are the principal products offered by our Structural Heart business:
Transcatheter Heart Valves. Transcatheter Heart Valve (TCV) technology represents a less invasive means to treat heart valve
disease and is designed to allow physicians to deliver replacement valves via a catheter through the body’s cardiovascular system,
eliminating the need to open the chest. Our TCVs include the CoreValve transfemoral aortic valve and Engager transapical aortic
valves as well as the Melody pulmonary valve. Melody has received CE Mark approval and U.S. FDAapproval under a Humanitarian
Device Exemption (HDE). CoreValve and Engager have both received CE Mark approval and CoreValve is currently being
clinically evaluated for U.S. approval.
Heart Valves. We offer a complete line of surgical valve replacement and repair products for damaged or diseased heart valves.
Our replacement products include both tissue and mechanical valves. Our replacement tissue valve product offerings include the
Mosaic bioprosthetic stented, Freestyle stentless, Hancock II stented, Enable sutureless tissue (CE Mark countries), and 3f
Biological tissue valves. Our mechanical valves include the Open Pivot valve. Our valve repair products include the Duran Flexible
and CG Future Band, CG Composite Annuloplasty Systems, Profile 3D Annuloplasty Ring, Simulus Ring portfolio, and Tri-Ad
Annuloplasty Ring.
Arrested Heart Surgery. In conventional coronary artery bypass graft procedures and heart valve surgery, the patient’s heart is
temporarily stopped, or arrested. The patient is placed on a circulatory support system that temporarily functions as the patient’s
heart and lungs and provides blood flow to the body. We offer a complete line of blood-handling products that form this circulatory
support system and maintain and monitor blood circulation and coagulation status, oxygen supply, and body temperature during
arrested heart surgery. Recently, our Affinity Fusion oxygenation system received both CE Mark and U.S. FDA approval and is
being launched globally. Affinity Fusion incorporates numerous innovations for patient safety and ease of use.
Beating Heart Surgery. To assist physicians performing beating heart surgery, we offer positioning and stabilization technologies.
These technologies include our Starfish 2 and Urchin heart positioners, which are designed to work in concert with our family of
Octopus tissue stabilizers.
Surgical Ablation. Our Cardioblate surgical ablation system, which includes the Cardioblate LP surgical ablation system,
Cardioblate navigator tissue dissector, and Cardioblate Cryoflex system, allows cardiac surgeons to create ablation lines during
cardiac surgery.
The charts below set forth net sales of our Structural Heart products as a percentage of our total net sales for each of the last three
fiscal years:
6%
94%
Fiscal Year 2011
(dollars in millions)
Structural Heart
$977
All Other
$14,531
7%
93%
Fiscal Year 2012
(dollars in millions)
All Other
$15,090
Structural Heart
$1,094
7%
93%
Fiscal Year 2013
(dollars in millions)
All Other
$15,457
Structural Heart
$1,133
4